Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has provided an announcement.
Cosmo Pharmaceuticals has received a positive opinion from the European Medicines Agency’s CHMP for the approval of Winlevi® for treating acne in adults and adolescents in Europe, following a successful re-evaluation. This approval marks a significant expansion for Winlevi® in the European market, offering a novel topical anti-androgen therapy for acne, and is expected to drive Cosmo’s growth across the region.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF64.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life science company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing. Founded in 1997 and headquartered in Dublin, Ireland, Cosmo designs, develops, and manufactures advanced healthcare solutions, aiming to improve the standard of care globally. The company collaborates with leading pharma and MedTech companies and has a presence in the USA and Italy.
Average Trading Volume: 23,438
Technical Sentiment Signal: Buy
Current Market Cap: CHF981.6M
For an in-depth examination of COPN stock, go to TipRanks’ Overview page.